ATYR

Business Context and Reporting Period

Company: Atyr Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 17, 2018
Context: The Company is an emerging growth company participating in the 2018 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This filing serves as a Regulation FD disclosure regarding preclinical research presentations.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on scientific disclosures rather than financial performance.

Material Changes

No material financial changes or operational updates regarding prior periods are reported in this filing. The primary update is the dissemination of preclinical data at a scientific conference.

Guidance, Outlook, and Management Commentary

Scientific Developments: The Company presented two preclinical posters regarding its immuno-oncology program based on the Resokine pathway:

• Poster 1: "Circulating levels of Resokine, a soluble modulator of the immune system, are upregulated in both experimental cancer models and in patients across multiple tumor types."
• Poster 2: "Antibodies targeting Resokine, a soluble immune modulator, inhibit tumor growth in syngeneic mouse models."

Legal Status of Information: The information provided, including the attached exhibits, is furnished and not deemed "filed" under Section 18 of the Exchange Act. It is not incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

• Verify the full text of the two poster presentations (Exhibits 99.1 and 99.2) on the Company's website.
• Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
• Review subsequent filings for any clinical trial updates or financial results, as this 8-K contains no financial data.